Kringle Pharma, Inc.
Notice Regarding the Introduction of the Executive Officer System
Starting October 1, 2026, the executive officer system will be introduced. The CEO will be the chief operating officer, with multiple executive officers appointed and currently held positions concurrently, and restricted stock units will be granted as compensation.
Key Figures
- Executive Officer System Introduction Resolution Date: 2026-09-16 (document date)
- Timing of introduction: 2026-10-01
- Newly appointed executive officers: Kiichi Adachi, Koichi Murakami, Taima Hayata, Yoshiyuki Chino, Kazuaki Kinjo
AI要約
Purpose of Introduction
This notice, published today, aims to establish an executive officer system to clearly delineate functions and authority across research and development, manufacturing, and business development in anticipation of progress in development stages and overseas expansion, enabling swift and agile execution. The CEO will be positioned as the top executive officer, and the company will strengthen its management foundation and enhance corporate value.
Human Resources Structure and Timing
Appointment and dismissal of executive officers are determined by the board of directors, terms are one year with the possibility of reappointment, and directors may concurrently serve as executive officers. The CEO will be the overall supervisor, and compensation will be granted in the form of restricted stock. The introduction date is October 1, 2026. As of the executive officer appointments on October 1, 2026, Kiichi Adachi will serve as CEO and Representative Director President, Koichi Murakami as Executive Officer General Affairs Head, Taima Hayata as Executive Officer Head of Pharmaceutical Development and Chief Pharmacist, Yoshiyuki Chino as Executive Officer Head of Reliability Assurance, and Kazuaki Kinjo as Head of the Corporate Strategy Office.
Kringle Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
